Книга В зоне риска. Тонкости защиты женского организма. Как ВПЧ проникает в наш организм, чем он опасен и что поможет избежать последствий, страница 56. Автор книги Дмитрий Лубнин

Разделитель для чтения книг в онлайн библиотеке

Онлайн книга «В зоне риска. Тонкости защиты женского организма. Как ВПЧ проникает в наш организм, чем он опасен и что поможет избежать последствий»

Cтраница 56

20. Siegel R.L., Miller K.D. and Jemal A. (2019), Cancer statistics, 2019. CA A Cancer J Clin, 69: 7–34. doi:10.3322/caac.21551

21. Beral V. Cancer of the cervix: a sexually-transmitted disease? Lancet 1974; i: 1037–40.

22. Bosch F.X., de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31:3–13.

23. Paba P., Bonifacio D., Di Bonito L., et al. Co-expression of HSV2 and Chlamydia trachomatis in HPV-positive cervical cancer and cervical intraepithelial neoplasia lesions is associated with aberrations in key intracellular pathways. Intervirology 2008; 51:230–4.

24. Moody C.A., Laimins L.A. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10:550–60.

25. Hellberg D., Nilsson S., Haley N.J., Hoffman D., Wynder E. Smoking and cervical intraepithelial neoplasia: nicotine and cotinine in serum and cervical mucus in smokers and non-smokers. Am J Obstet Gynecol 1988; 158:910–3.

26. Gadducci A., Barsotti C., Cosio S., Domenici L., Riccardo Genazzani A. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol 2011; 27(8):1–8.

27. Kojic E.M., Cu-Uvin S. Update: human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals. Curr Opin Oncol 2007; 19:464–9.

28. Martin M.P., Borecki I.B., Zhang Z., et al. HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer. Immunogenetics 2010; 62:761–5.

29. Cox J.T. В: Lonky N., ed. Management of precursor lesions of cervical carcinoma: history, host defense, and a survey of modalities. Obstet Gynecol Clin North Am 2002; 29(4):751–85.

30. Gollnick H., Barrasso R., Jappe U., et al. Safety and efficacy of imiquimod 5 % cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int J STD AIDS2001; 12:22–8.

31. Ho GYF, Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423–8.

32. Einstein M.H., Burk R.D. Persistent human papillomavirus infection: definitions and clinical implications. Papillomavirus Rep 2001; 12:119–23.

33. Ostor A.G. Natural history of CIN: a critical review. Int J Gynecol Pathol 1993; 12:186–92.

34. Burghardt E., Ostor A.G. Site and origin of squamous cervical cancer: a histomorphologic study. Obstet Gynecol 1983; 62:117–26.

35. Selvaggi S.M. Reporting of atypical squamous cells, cannot exclude a high-grade squamous intraepithelial lesion (ASC-H) on cervical samples: is it significant? Diagn Cytopathol 2003; 29:38–41.

36. Hopman E.H., Kenemans P., Helmerhorst T.J.M. Positive predictive rate of colposcopic examination of the cervix uteri: an overview of the literature. Obstet Gynecol Survey 1998; 53:97–106.

37. Gage J.C., Hanson V.W., Abbey K., et al.; The ASCUS LSIL Triage Study (ALTS) Group. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006; 108(2):264–72.

38. Sze E., Rosenzweig B., Birenbaum D., et al. Excisional conization of the cervix-uteri. J Gynecol Surg 1989; 5:325–31.

39. Ferenczy A., Choukroun D., Arseneau J. Loop electrosurgical excision procedure for squamous intraepithelial lesions of the cervix: advantages and potential pitfalls. Obstet Gynecol 1996; 87:332–7.

40. Davey D.D., Neal M.H., Wilbur D.C., Colgan T.J., Styer P.E., Mody D.R. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med 2004; 128:1224–9.

41. Stoler M.H., Wright T.C. Jr, Sharma A., Apple R., Gutekunst K., Wright T.L.; the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) HPV Study Group. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011; 135:468–75.

42. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188:1383–92.

43. Jones B.A., Davey D.D. Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med 2000; 124:672–81.

44. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., Dillner J. Chapter 9: clinical applications of HPV testing: a summary of metaanalyses. Vaccine 2006; 24(suppl 3): S78–89.

45. Moscicki A.B., Ma Y., Wibbelsman C., et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010; 116(6):1373–80.

46. Monteiro D.L., Trajano A.J., Russomano F.B., Silva K.S. Prognosis of intraepithelial cervical lesion during adolescence in up to two years of follow-up. J Pediatr Adolesc Gynecol 2010; 23(4):230–6.

47. Sherman M.E., Schiffman M.H., Lorincz A.T., et al. Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am J Clin Pathol 1994; 102(2):182–7.

48. Koeneman M.M., Essers B.A., Gerestein C.G., van de Sande A.J., Litjens R.J., Boskamp D., Goossens M.F., Beekhuizen H.J., Kruitwagen R.F., Kruse A.J., Dirksen C.D. Treatment of Cervical Intraepithelial Neoplasia: Patients Preferences for Surgery or Immunotherapy with Imiquimod J Immunother. 2017 Feb 17.

49. Teymouri M., Pirro M., Johnston T.P., Sahebkar A. Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: A review of chemistry, cellular, molecular, and preclinical features. Biofactors. 2017 May 6; 43(3):331–346.

50. Leda Gattoc, Paula M. Frew, Shontell N. Thomas, Kirk A. Easley, Laura Ward, H-H Sherry Chow, Chiemi A. Ura, Lisa Flowers Phase I dose-escalation trial of intravaginal curcumin in women for cervical dysplasia Open Access J Clin Trials. 2017; 9: 1–10. Published online 2016 Dec 22. doi: 10.2147/OAJCT.S105010.

51. Santesso N., Mustafa R.A., Wiercioch W., Kehar, Gandhi S., Chen Y., Cheung A., Hopkins J., Khatib R., Ma B., Mustafa A.A., Lloyd N., Wu D., Broutet N., Schünemann H.J. Systematic reviews and meta-analyses of benefits and harms of cryotherapy, LEEP, and cold knife conization to treat cervical intraepithelial neoplasia Int J Gynaecol Obstet. 2016 Mar; 132(3):266–71.

52. Ghaem-Maghami S., Sagi S., Majeed G., Soutter W.P. Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis. Lancet Oncol 2007; 8(11):985–93.

53. Armarnik S., Sheiner E., Piura B., Meirovitz M., Zlotnik A., Levy A. Obstetric outcome following cervical conization. Arch Gynecol Obstet 2011; 283(4):765–9.

Поиск по сайту